LOTTE BIOLOGICS made a notable mark at the CPhI Japan 2024 Conference.

The CTO, Kern Chang(장건희), Ph.D., delivered an presentation on the forefront of ADC(Antibody-Drug Conjugate) technology, highlighting the latest trends and introducing our upcoming ADC facility at our Syracuse site.

ADC facility at Syracuse site is on track to be GMP READY by Q1 2025, and LOTTE BIOLOGICS is at the forefront of ADC services, engaging in strategic collaborations with industry pioneers such as NJ Bio, Inc. and Kanaph Therapeutics.